- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00705224
Effect of Insulin Resistance on the Safety and Efficacy of Pegylated Interferon and Ribavirin Treatment in HCV (Study P05562)
Observational Multicenter Study to Evaluate Influence of Insulin Resistance on the Safety and Efficacy (as Measured by Sustained Virological Response) of Treatment With Any Pegylated Interferon and Ribavirin (Standard of Care) in Different Populations of HCV Patients in Russia.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Studientyp
Einschreibung (Tatsächlich)
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Confirmed diagnosis of CHC according to local regulations
- Naïve Pegylated Interferon (PEG-IFN) CHC patient
- No contraindications for PEG-IFN CHC therapy
- Negative urine pregnancy test result (for females of childbearing potential) documented within the 24-hour period prior to the first dose of study drugs. Additionally, all female patients of childbearing potential and all males with female partners of childbearing potential must use two forms of effective contraception (combined) during treatment and 6 months after treatment end
- Willingness to give written informed consent and willingness to participate in and comply with the study requirements.
Exclusion Criteria:
- PEG-IFN treatment in history
- Contraindications for PEG-IFN CHC therapy
- Females who are pregnant or breast-feeding
- Male partners of females who are pregnant
- Potentially unreliable participants, and those judged by the investigator to be unsuitable for the study.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
---|---|
Patients with chronic hepatitis C
Naïve patients with chronic hepatitis C (CHC) of any genotype will be treated with a standard treatment regimen (pegylated interferon and ribavirin) according to routine clinical practice in Russia.
|
Routine treatment with a combination of any pegylated interferon and ribavirin was used according to the label/local practice in Russia. The treatment course duration complied with the labeled dosage regimen. Each dose of pegylated interferon was administered as a subcutaneous injection calculated as 1.5 mcg/kg once a week. Therapy duration varied from 24 to 48 weeks depending on Hepatitis C virus (HCV) genotype, viral load, activity and stage of hepatitis C. The Sponsor did not provide formal drug supply.
Andere Namen:
Routine treatment with a combination of any pegylated interferon and ribavirin was used according to the label/local practice in Russia. The treatment course duration complied with the labeled dosage regimen. Ribavirin was taken orally as 200 mg gelatinous capsules. The daily dose varied from 800 to 1200 mg (depending on patient's body weight) twice daily in the morning and in the evening with meal. Therapy duration varied from 24 to 48 weeks depending on HCV genotype, viral load, activity and stage of hepatitis C. The Sponsor did not provide formal drug supply.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Percentage of Participants Who Achieved Sustained Virological Response as Assessed at End of Study
Zeitfenster: 24 weeks following completion of 24 or 48 weeks of therapy
|
Sustained Virological response (SVR) was assessed at the end of the study (Visit 4) to investigate the presence or absence of SVR.
SVR was defined as undetectable plasma hepatitis C virus RNA (HCV-RNA) at 24 weeks after termination of treatment.
Visit 4 was considered Week 48 or Week 72 depending on a treatment duration of 24 or 48 weeks respectively.
|
24 weeks following completion of 24 or 48 weeks of therapy
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Percentage of Participants Who Achieved Sustained Virological Response as Assessed at End of Study by HCV Genotype and Presence of Insulin-Resistance at Baseline
Zeitfenster: 24 weeks following completion of 24 or 48 weeks of therapy
|
SVR was assessed at the end of the study (Visit 4) by HCV genotype (I, II, III, or other) and presence of insulin-resistance at baseline (defined as Homeostasis model assessment - of insulin-resistance [HOMA-IR] >3) to investigate the presence or absence of SVR.
SVR was defined as undetectable plasma HCV-RNA at 24 weeks after termination of treatment.
Visit 4 was considered Week 48 or Week 72 depending on a treatment duration of 24 or 48 weeks respectively.
|
24 weeks following completion of 24 or 48 weeks of therapy
|
Percentage of Participants Who Achieved Response Following Treatment as Assessed at End of Treatment by HCV Genotype and Presence of Insulin-Resistance at Baseline
Zeitfenster: Week 24 or 48 after treatment start
|
Response following treatment (RFT) was assessed at the end of treatment (Visit 3) by HCV genotype (I, II, III, or other) and presence of insulin-resistance at baseline (defined as HOMA-IR >3) to investigate the presence or absence of RFT.
RFT was defined as undetectable plasma HCV-RNA at end of treatment.
Visit 3 was considered Week 24 or Week 48 after treatment start depending on treatment duration.
|
Week 24 or 48 after treatment start
|
Percentage of Participants Who Demonstrated Virological Relapse as Assessed at End of Study by HCV Genotype and Presence of Insulin-Resistance at Baseline
Zeitfenster: 24 weeks following completion of 24 or 48 weeks of therapy
|
Virological relapse (VR) was assessed at the end of the study (Visit 4) by HCV genotype (I, II, III, or other) and presence of insulin-resistance at baseline (defined as HOMA-IR >3) to investigate the percentage of participants who demonstrated VR.
VR was defined as undetectable plasma HCV-RNA (RFT +) at end of treatment (Visit 3- considered Week 24 or Week 48 after treatment start depending on treatment duration), but lost RFT (considered sustained non-Responders) at end of study (Visit 4- considered Week 48 or Week 72 depending on a treatment duration of 24 or 48 weeks respectively).
|
24 weeks following completion of 24 or 48 weeks of therapy
|
Percentage of Participants Who Achieved Early Virological Response as Assessed at Visit 2 by HCV Genotype and Presence of Insulin-Resistance at Baseline
Zeitfenster: Week 12 after treatment start
|
Early Virological response (EVR) was assessed at 12 weeks after treatment start (Visit 2) by HCV genotype (I, II, III, or other) and presence of insulin-resistance at baseline (defined as HOMA-IR >3) to investigate the percentage of participants who achieved EVR.
EVR was defined as a substantial (greater than 2 log10) decrease in viral load (measured as International Units/milliliter) and/or negative Polymerase chain reaction (PCR)-based viral load qualitative result as assessed at visit 2 of the study.
|
Week 12 after treatment start
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Verdauungssystems
- Störungen des Glukosestoffwechsels
- Stoffwechselerkrankungen
- RNA-Virusinfektionen
- Viruserkrankungen
- Infektionen
- Durch Blut übertragene Infektionen
- Übertragbare Krankheiten
- Leberkrankheiten
- Flaviviridae-Infektionen
- Hepatitis, viral, menschlich
- Enterovirus-Infektionen
- Picornaviridae-Infektionen
- Hepatitis, chronisch
- Hyperinsulinismus
- Hepatitis
- Hepatitis A
- Hepatitis C
- Insulinresistenz
- Hepatitis C, chronisch
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antiinfektiva
- Antivirale Mittel
- Antimetaboliten
- Antineoplastische Mittel
- Interferone
- Ribavirin
Andere Studien-ID-Nummern
- P05562
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Hepatitis C, chronisch
-
Tripep ABInovio PharmaceuticalsUnbekanntChronische Hepatitis-C-VirusinfektionSchweden
-
Trek Therapeutics, PBCAbgeschlossenChronische Hepatitis C | Hepatitis-C-Genotyp 1 | Hepatitis C (HCV) | Hepatitis-C-VirusinfektionVereinigte Staaten, Neuseeland
-
Trek Therapeutics, PBCAbgeschlossenChronische Hepatitis C | Hepatitis C (HCV) | Hepatitis-C-Genotyp 4 | Hepatitis-C-VirusinfektionVereinigte Staaten
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsZurückgezogenChronische Hepatitis-C-VirusinfektionIsrael
-
Hadassah Medical OrganizationUnbekanntChronische Hepatitis-C-VirusinfektionIsrael
-
AbbVieAbgeschlossenChronische Hepatitis C | Hepatitis C (HCV) | Hepatitis-C-Genotyp 1a
-
AbbVie (prior sponsor, Abbott)AbgeschlossenChronische Hepatitis C | Hepatitis-C-Genotyp 1 | Hepatitis C (HCV)Vereinigte Staaten, Australien, Kanada, Frankreich, Deutschland, Neuseeland, Puerto Rico, Spanien, Vereinigtes Königreich
-
Beni-Suef UniversityAbgeschlossenChronische Hepatitis-C-VirusinfektionÄgypten
-
Humanity and Health Research CentreBeijing 302 HospitalAbgeschlossenChronische Hepatitis-C-InfektionChina
-
AbbVieAbgeschlossenHepatitis-C-Virus | Chronisches Hepatitis-C-Virus
Klinische Studien zur Pegylated Interferon
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); Horizon Pharma USA, Inc.BeendetMyxoides Liposarkom | Synoviales Sarkom | Rundzelliges LiposarkomVereinigte Staaten
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)AbgeschlossenTumore des Gehirns und des zentralen NervensystemsVereinigte Staaten
-
Digna Biotech S.L.AbgeschlossenChronische Hepatitis-C-Virusinfektion | Genotyp 1 | Behandlungserfahrene Patienten | RückfälleSpanien
-
Mongolian National University of Medical SciencesMongolian National Cancer CenterRekrutierungHPV-Infektion | Zervikale DysplasieMongolei
-
Ainos, Inc. (f/k/a Amarillo Biosciences Inc.CytoPharm, Inc.AbgeschlossenHepatitis C, chronischTaiwan
-
Royal Marsden NHS Foundation TrustAbgeschlossenMultiples MyelomVereinigtes Königreich
-
The Cleveland ClinicNational Cancer Institute (NCI)AbgeschlossenMelanom | Sarkom | Lymphom | Nierenkrebs | Brustkrebs | Multiples Myelom | Nicht näher bezeichneter erwachsener solider Tumor, protokollspezifischVereinigte Staaten
-
SPP Pharmaclon Ltd.North-Western State Medical University named after I.I.MechnikovAbgeschlossenRNA-Virusinfektionen | Lentivirus-Infektionen | Tuberkulose, Lungen | Menschlicher Immunschwächevirus | HIV-Koinfektion | Aids/HIV-ProblemRussische Föderation
-
SPP Pharmaclon Ltd.RekrutierungLungentuberkuloseRussische Föderation
-
SPP Pharmaclon Ltd.AbgeschlossenAmbulant erworbene PneumonieRussische Föderation